Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors ExpectThe Motley Fool • 10/08/26
Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not24/7 Wall Street • 10/08/26
The Crash-Proof Portfolio: 5 Elite Dividend Stocks Built to Survive a Market Meltdown24/7 Wall Street • 10/07/26
Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Share Its Reliability24/7 Wall Street • 10/06/26
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 10/06/26
Johnson & Johnson or Procter & Gamble: If I Could Only Own 1 Dividend King for 20 Years, This Is It24/7 Wall Street • 10/06/26
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 10/05/26
Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson.The Motley Fool • 10/05/26
J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to WatchZacks Investment Research • 10/02/26
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapyPRNewsWire • 10/02/26
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?The Motley Fool • 10/01/26
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue ScaleThe Motley Fool • 10/01/26
New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with MenopauseBusiness Wire • 10/01/26
5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)24/7 Wall Street • 10/01/26
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.The Motley Fool • 10/01/26
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record HighThe Motley Fool • 09/30/26